Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Apomorphine for Sleep Disorders in Parkinson's Disease
NCT02940912Phase 4Completed
- Sponsor
- Clinique Beau Soleil
- Start
- Jan 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of apomorphine in Parkinson's disease (PD) (2 arms), sponsored by Clinique Beau Soleil. Primary endpoint: Parkinson's Disease Sleep Scale 2 at 53 days. Started Jan 2017; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02940912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940912.